{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:25:56Z","timestamp":1740111956621,"version":"3.37.3"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["NKI 2012-5685"],"award-info":[{"award-number":["NKI 2012-5685"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115083","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T02:10:24Z","timestamp":1729390224000},"page":"115083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study"],"prefix":"10.1016","volume":"213","author":[{"given":"A.","family":"van Ommen-Nijhof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.G.","family":"Steenbruggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.G.","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Daletzakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Delfos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.M.","family":"Siemerink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Heijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.A.","family":"Mandjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.H.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.T.","family":"Vrancken Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115083_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2021.12.031","article-title":"Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study","volume":"164","author":"Dalenc","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.115083_bib2","article-title":"Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de novo metastatic breast cancer","volume":"5","author":"Steenbruggen","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"9","key":"10.1016\/j.ejca.2024.115083_bib3","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1245\/s10434-012-2333-3","article-title":"Limited M1 disease: a significant prognostic factor for stage IV breast cancer","volume":"19","author":"Nguyen","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.115083_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12282-012-0347-0","article-title":"Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review","volume":"19","author":"Kobayashi","year":"2012","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejca.2024.115083_bib5","article-title":"Survival and prognostic factors in oligometastatic breast cancer","author":"van Ommen-Nijhof","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2024.115083_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","article-title":"Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade","volume":"131","author":"Milano","year":"2019","journal-title":"Radio; Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.115083_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ejca.2024.115083_bib8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2024.115083_bib9","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.22.01482","article-title":"Oligometastases: Emerging Evidence","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.115083_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1083-8791(00)70018-8","article-title":"High-dose chemotherapy in breast cancer: the end of the beginning?","volume":"6","author":"Antman","year":"2000","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.ejca.2024.115083_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CCO.0b013e328324f48b","article-title":"High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?","volume":"21","author":"Nieto","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.115083_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3655","article-title":"Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy","volume":"16","author":"Vollebergh","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.5-1-1","article-title":"High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer","volume":"5","author":"Peters","year":"2000","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ejca.2024.115083_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc3342","article-title":"The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance","volume":"12","author":"Bouwman","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7035","key":"10.1016\/j.ejca.2024.115083_bib15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejca.2024.115083_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.115083_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00018-011-0809-0","article-title":"Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers","volume":"69","author":"Vollebergh","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-020-01313-7","article-title":"BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer","volume":"22","author":"Lips","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2024.115083_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cancergen.2023.02.001","article-title":"Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer","volume":"272-273","author":"Liu","year":"2023","journal-title":"Cancer Genet"},{"issue":"2","key":"10.1016\/j.ejca.2024.115083_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000480","article-title":"Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?","volume":"4","author":"Pellegrino","year":"2019","journal-title":"ESMO Open"},{"issue":"22","key":"10.1016\/j.ejca.2024.115083_bib21","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115083_bib22","unstructured":"Richtlijnendatabase (Dutch breast cancer guideline). Accessed August 1, 2022. \u3008https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/pathologie\/receptorbepaling.html\u3009."},{"issue":"5","key":"10.1016\/j.ejca.2024.115083_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1524-4741.2002.08002.x","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease","volume":"8","author":"Rivera","year":"2002","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000421-198402000-00006","article-title":"Combined modality approach in breast cancer with isolated or multiple metastases","volume":"7","author":"Buzdar","year":"1984","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jso.2930120105","article-title":"Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)","volume":"12","author":"Buzdar","year":"1979","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115083_bib27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/cncr.21305","article-title":"Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors","volume":"104","author":"Hanrahan","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.115083_bib28","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.115083_bib29","unstructured":"M.; FP, K.; AN, K.; B, et al. The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organisation for Research and Treatment of Cancer; 2001."},{"issue":"16_","key":"10.1016\/j.ejca.2024.115083_bib30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2024.115083_bib31","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1002\/cncr.29681","article-title":"Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy","volume":"121","author":"Bishop","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.115083_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-019-05406-6","article-title":"Long-term outcome with targeted therapy in advanced\/metastatic HER2-positive breast cancer: The Royal Marsden experience","volume":"178","author":"Battisti","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-017-4489-9","article-title":"Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis","volume":"167","author":"Niikura","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.115083_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003139.pub2","article-title":"High\u2010dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer","volume":"3","author":"Farquhar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ejca.2024.115083_bib35","article-title":"High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer","volume":"2016","author":"Farquhar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ejca.2024.115083_bib36","first-page":"1731","article-title":"Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease","volume":"5","author":"Nieto","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2024.115083_bib37","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bbmt.2012.01.021","article-title":"Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced\/inflammatory, and metastatic breast cancer","volume":"18","author":"VanderWalde","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"10.1016\/j.ejca.2024.115083_bib38","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.3390\/cancers14205000","article-title":"Oligometastatic breast cancer patients treated with high-dose chemotherapy and targeted radiation: long-term follow-up of a phase II Trial","volume":"14","author":"Ladbury","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.ejca.2024.115083_bib39","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1200\/JCO.2010.32.5910","article-title":"High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials","volume":"29","author":"Berry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2024.115083_bib40","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1200\/JCO.2010.32.5936","article-title":"High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials","volume":"29","author":"Berry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.115083_bib41","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.ejca.2024.115083_bib42","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","article-title":"Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer","volume":"23","author":"Zhao","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2024.115083_bib43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.115083_bib44","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.115083_bib45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41523-023-00580-9","article-title":"High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial","volume":"9","author":"Vliek","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.115083_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ejca.2024.115083_bib48","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1158\/1078-0432.CCR-19-2933","article-title":"Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors","volume":"26","author":"Vidula","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.115083_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102462","article-title":"Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?","volume":"110","author":"Miglietta","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"34","key":"10.1016\/j.ejca.2024.115083_bib50","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1200\/JCO.2007.11.2813","article-title":"Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life","volume":"25","author":"Buijs","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.115083_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/sj.bjc.6603454","article-title":"Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer","volume":"95","author":"Malinovszky","year":"2006","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.115083_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2024.115083_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924012140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924012140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:33:55Z","timestamp":1733992435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924012140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"alternative-id":["S0959804924012140"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115083","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115083"}}